European Journal of Clinical Pharmacology

, Volume 27, Issue 1, pp 67–74 | Cite as

Inhibition of platelet function by a controlled release acetylsalicylic acid formulation — Single and chronic dosing studies

  • M. S. Roberts
  • L. J. McLeod
  • P. A. Cossum
  • J. H. Vial
Originals

Summary

The extent to which a controlled release acetylsalicylic acid (ASA) formulation inhibited platelet function has been evaluated in single and chronic dosing studies. In the single dose study, the platelet inhibitory effect of the controlled release formulation was compared with that of an equivalent dose of soluble ASA and an equimolar dose of sodium salicylate (SA). In the chronic dosing study, ASA dose-response curves for platelet function, including cyclooxygenase activity, were determined for various doses (20–1300 mg) of the controlled release (enteric coated pellets) ASA formulation taken by volunteers daily for one week. Platelet function was assessed by the degree of inhibition of aggregation for several aggregating agents, and the degree of inhibition of activity of platelet cyclooxygenase quantified by the estimation of malondialdehyde (MDA) production. Plasma ASA and SA concentrations were also determined in each study. The controlled release product inhibited platelet function to the same extent as an equimolar dose of soluble ASA, but did so with much lower and sometimes undetectable peak systemic plasma ASA concentrations. SA, the direct metabolite of aspirin, did not have any effect on platelet function. The ASA dose-platelet function response curves obtained from chronic dosing with the controlled release formulation appeared to be similar to those reported previously for the soluble product. The inhibition of platelet function appeared to be unrelated to plasma ASA concentrations.

Key words

acetylsalicylic acid platelet function salicylate controlled release formulation single dosing continuous dosing healthy volunteers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ali M, McDonald JWD, Thiessen JJ, Coates PE (1980) Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 11: 9–13PubMedGoogle Scholar
  2. 2.
    Aspirin Myocardial Infarction Study Research Group (1980) A randomized controlled trial of aspirin in persons recovered from myocardial infarction. J Am Med Assoc 243: 661–672Google Scholar
  3. 3.
    Baker RI, Pitney WK (1982) How much aspirin to inhibit platelet function? Med J Aust 2: 376–377PubMedGoogle Scholar
  4. 4.
    Blair IA, Barrow SE, Waddell KA, Lewis PJ, Dollery CT (1982) Prostacyclin is not a circulating hormone in man. Prostaglandins 23: 579–589CrossRefPubMedGoogle Scholar
  5. 5.
    Born GVR (1962) Aggregation of platelets by adenosine diphosphate and its reversal. Nature 194: 927–929PubMedGoogle Scholar
  6. 6.
    Brantmark B, Wåhlin-Boll E, Melander A (1982) Bioavailability of acetylsalicylic acid and salicylic acid from rapid and slow release formulations, and in combination with dipyridamol. Eur J Clin Pharmacol 22: 309–314CrossRefPubMedGoogle Scholar
  7. 7.
    Burch JW, Stanford N, Majerus PW (1978) Inhibition of platelet prostaglandin synthesis by oral aspirin. J Clin Invest 61: 314–319PubMedGoogle Scholar
  8. 8.
    Catalano PM, Smith JB, Murphy S (1981). Platelet recovery from aspirinin vivo; differing patterns under various assay conditions. Blood 57: 99–105.PubMedGoogle Scholar
  9. 9.
    Cerletti C, Livio M, DeGaetano G (1981). Non-steroidal anti-inflammatory drugs react with two sites on platelet cyclooxygenase. Evidence fromin vivo drug interaction studies in rats. Biochem Biophys Acta 714: 122–126.Google Scholar
  10. 10.
    Elwood PC, Sweetman PM (1979). Aspirin and secondary mortality after myocardial infarction. Lancet 2: 1313–1315.PubMedGoogle Scholar
  11. 11.
    Emms H, Lewis CP, Watts IS (1982). The role of thromboxane A2 (TxA2) and ADP in collagen-induced platelet aggregation. Br J Pharmacol 75: 167PGoogle Scholar
  12. 12.
    Fields WS, Lemak NA, Frankowski RF, Hardy RJ (1977). Controlled trial of aspirin in cerebral ischaemia. Stroke 8: 301–314PubMedGoogle Scholar
  13. 13.
    Fitzgerald GA, Oates JA, Hawiger J, Mass RL, Roberts LJ, Lawson JA, Brash AR (1983). Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71: 676–688PubMedGoogle Scholar
  14. 14.
    Flower RJ, Cheung HS, Cushman DW (1973). Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonate oxygenase (prostaglandin synthetase) system of bovine seminal vesicles. Prostaglandins 4: 325–341CrossRefPubMedGoogle Scholar
  15. 15.
    Gallus AS (1981) Prostacyclin and blood coagulation? What therapeutic implications? Curr Ther 22 [8]: 19–22Google Scholar
  16. 16.
    Hanley SP, Bevan J, Cockbill SR, Heptinstall S (1981) Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet 1: 969–971PubMedGoogle Scholar
  17. 17.
    Haslam RJ, McGlenaghan MD (1981) Measurement of circulating prostacyclin. Nature 292: 364–366PubMedGoogle Scholar
  18. 18.
    Hoogendijk EMG, Ten Cate JW (1980). Aspirin and platelets. Lancet 1: 93–94PubMedGoogle Scholar
  19. 19.
    Lorenz R, Siess W, Weber PC (1981) Effects of very low versus standard dose acetylsalicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man. Eur J Pharmacol 70: 511–515CrossRefPubMedGoogle Scholar
  20. 20.
    McLeod LJ, Cossum PA, Roberts MA, Vial JH (1981) The effects of sodium salicylate, soluble aspirin and enteric coated aspirin on platelet activity. Aust J Pharm Sci 10: 51Google Scholar
  21. 21.
    Masotti G, Poggesi L, Galanti G, Abbate R, Neri Serneri GG (1979) Differential inhibition of prostacyclin production and platelet aggregation. Lancet 2: 1213–1216PubMedGoogle Scholar
  22. 22.
    Moncada S, Vane JR (1980) Biological significance and therapeutic potential of prostacyclin. J Med Chem 23 [6]: 591–593CrossRefPubMedGoogle Scholar
  23. 23.
    Nuotto E, Gordin A, Paasonen MK, Metsä-Ketelä T, Lamminsivu U (1983) Effects of acetylsalicylic acid on plasma thromboxane B2 and platelet aggregation in man. Eur J Clin Pharmacol 25: 313–317CrossRefPubMedGoogle Scholar
  24. 24.
    Patrignani P, Filabozzi P, Patrona C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69: 1366–1372PubMedGoogle Scholar
  25. 25.
    Preston PE, Whipps S, Jackson CA, French AJ, Wyld PJ, Stoddard CJ (1981) Inhibition of prostacyclin and platelet thromboxane A2 after low dose aspirin. N Engl J Med 304: 76–79PubMedGoogle Scholar
  26. 26.
    Roth GJ, Stanford N, Majerus PW (1975) Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci 73: 3073–3076Google Scholar
  27. 27.
    Rowland M, Riegleman S, Harris PA, Sholkoff SD (1972) Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 61: 379–385PubMedGoogle Scholar
  28. 28.
    Rumble RH, Roberts MS, Wanwimolruk S (1981) Determination of aspirin and its major metabolites in plasma by high performance liquid chromatography without solvent extraction. J Chromatogr Biomed Appl 225: 252–268Google Scholar
  29. 29.
    Steer ML, MacIntyre DE, Levine L, Salzman EW (1980) Is prostacyclin a physiologically important circulating antiplatelet agent? Nature 283: 194–195CrossRefPubMedGoogle Scholar
  30. 30.
    The Canadian Co-operative Study Group (1978) A randomized trial New Engl J Med 229: 53–59Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • M. S. Roberts
    • 1
  • L. J. McLeod
    • 2
  • P. A. Cossum
    • 1
  • J. H. Vial
    • 3
  1. 1.School of PharmacyUniversity of TasmaniaHobartAustralia
  2. 2.Department of PhysiologyUniversity of TasmaniaHobartAustralia
  3. 3.Department of MedicineUniversity of TasmaniaHobartAustralia

Personalised recommendations